Melanie F. Von Brandenstein

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

The importance of specific antibodies in VIM-3 research: addressing a key methodological flaw.

The importance of specific antibodies in VIM-3 research: addressing a key methodological flaw.

Journal: Medicina

Published: June 22, 2026

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.

Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors.

Journal: Journal of cancer research and clinical oncology

Published: August 06, 2025

Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall Survival.

Very Early Relapse (< 1 year) in de novo Metastatic Seminoma is Associated With Reduced Overall Survival.

Journal: Clinical genitourinary cancer

Published: January 31, 2025

The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker.

The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker.

Journal: Oral diseases

Published: January 21, 2025

Vimentin 3 expression in odontogenic keratocysts - a molecular and immunohistochemical study.

Vimentin 3 expression in odontogenic keratocysts - a molecular and immunohistochemical study.

Journal: Polish journal of pathology : official journal of the Polish Society of Pathologists

Published: January 01, 2025

Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate

Next generation sequencing (NGS)-based molecular panel analysis for metastatic prostate cancer: how often can we detect druggable mutations? : NGS for metastatic adenocarcinoma of the prostate

Journal: Urologie (Heidelberg, Germany)

Published: November 26, 2024

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy.

TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy.

Journal: World journal of urology

Published: August 14, 2024

Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma.

Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma.

Journal: BJU international

Published: June 19, 2024

Advancements in bioengineering for descemet membrane endothelial keratoplasty (DMEK).

Advancements in bioengineering for descemet membrane endothelial keratoplasty (DMEK).

Journal: NPJ Regenerative medicine

Published: June 13, 2024

The influence of obesity, diabetes mellitus and smoking on fuchs endothelial corneal dystrophy (FECD).

The influence of obesity, diabetes mellitus and smoking on fuchs endothelial corneal dystrophy (FECD).

Journal: Scientific reports

Published: January 21, 2024

Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p.

Improved Analysis of Prostate Cancer: VIM3, ATG7 and P53 Form a Complex and Activate miRNA 371a-3p.

Journal: Anticancer research

Published: March 16, 2023

Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.

Differentially expressed messenger RNA/proteins can distinguish teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection tissue.

Journal: Cancer

Published: August 15, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026